US00847X1046
US00847X1046
Agios Pharmaceuticals, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 1.9B EUR | 2.21B EUR | 2.01B EUR | 1.59B EUR |
Enterprise Value | 1.32B EUR | 2.14B EUR | 1.93B EUR | 1.54B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -7.91x | -- | -- | -- |
Price to Sales | 19.31x | 22.49x | 30.39x | 35.12x |
Price to Book | 1.85x | 2.16x | 0.83x | 1.33x |
EV/Revenue | 13.42x | 21.8x | 29.22x | 34.04x |
EV/EBITDA | -2.91x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -14.46% | -17.64% | -19.66% | -17.29% |